KYMAB LIMITED
Get an alert when KYMAB LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-07 (in 5mo)
Last made up 2025-09-23
Watchouts
None on the register
Cash
£68K
+142.9% vs 2023
Net assets
-£861M
-77.7% vs 2023
Employees
89
-38.6% vs 2023
Profit before tax
-£383M
-94.3% vs 2023
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£182,803,000 | -£350,414,000 | |
| Profit before tax | -£196,948,000 | -£382,598,000 | |
| Net profit | -£192,090,000 | -£376,879,000 | |
| Cash | £28,000 | £68,000 | |
| Total assets less current liabilities | -£483,662,000 | -£860,321,000 | |
| Net assets | -£484,372,000 | -£860,955,000 | |
| Equity | -£484,372,000 | -£860,955,000 | |
| Average employees | 145 | 89 | |
| Wages | £10,117,000 | £8,755,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | 37.8% | 40.7% | |
| Current ratio | 0.03x | 0.02x | |
| Interest cover | -8.80x | -9.50x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The company has not seen a significant impact on its business to date from the situation in Ukraine and the Middle East conflict. The Directors' assessment is that the ongoing situations in Ukraine and the Middle East and the associated impact on the economy will not have a significant impact on the company. Therefore the Directors consider the adoption of the going concern basis in preparing the financial statements is appropriate. The company is in a net liability position of £861.0 million and made a loss of £376.9 million. Furthermore, the Directors have received confirmation from Sanofi SA, the ultimate parent company, confirming their ability to support the company to 31 December 2026.”
Significant events
- “Amlitelimab (KY1005) successfully completed Phase 2a clinical studies in 2020 and its first Phase 2b studies in 2024. Other Phase 2b studies are ongoing and the first Phase 3 study has begun.”
- “There have been no significant events affecting the company since the year end.”
- “Following a review of the R&D site footprint, it was communicated on the 1 February 2024 that research operations in Cambridge UK (acquired through Kymab) would cease as of June 2024. Cambridge UK's intergrated Intelliselect platform, including the Kymouse and associated discovery technologies, have been fully intergrated into the Sanofi research and development organisation. The Infectious Diseases team who do research work on behalf of the BMGF (Bill and Melinda Gates Foundation) will be retained at the Cambridge site.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 22 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MOHAMED, Walaa Mostafa Abbas Awad | Director | 2026-03-25 | Oct 1977 | Egyptian |
| TILLETT, Gordon Michael | Director | 2021-08-01 | Nov 1965 | British |
Show 22 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HYLAND, Anne | Secretary | 2015-06-16 | 2021-04-08 |
| OLSWANG COSEC LIMITED | Corporate Secretary | 2009-09-23 | 2014-03-25 |
| TAYLOR WESSING SECRETARIES LIMITED | Corporate Secretary | 2014-03-25 | 2021-04-08 |
| BRADLEY, Allan, Professor | Director | 2010-03-03 | 2021-04-08 |
| CHISWELL, David John | Director | 2012-09-28 | 2019-01-01 |
| DAVID, Richard Jon | Director | 2012-09-28 | 2014-09-09 |
| FRIEDRICH, Glenn Alfons, Dr | Director | 2009-09-23 | 2010-03-30 |
| GARCIA-ECHEVERRIA, Carlos Jesus | Director | 2021-04-08 | 2021-06-30 |
| GIRARD, Jérémie | Director | 2021-04-08 | 2021-09-01 |
| GROENDAHL, Christian, Dr | Director | 2013-09-16 | 2015-02-10 |
| HOWD, Adrian Graham | Director | 2015-04-28 | 2016-11-23 |
| ITIN, Christian Martin | Director | 2012-09-28 | 2016-11-23 |
| KHAN, Usman | Director | 2021-08-01 | 2026-03-25 |
| KIFF, Genevieve | Director | 2010-06-01 | 2012-09-28 |
| MARTIN, George Kelly | Director | 2015-04-28 | 2016-11-23 |
| PATEL, Lisha Nagin | Director | 2014-09-09 | 2016-11-23 |
| PATEL, Naimish | Director | 2021-04-08 | 2021-09-01 |
| RINK, Timothy James, Dr | Director | 2010-06-01 | 2016-11-23 |
| SANDHAM, Andrew Peter | Director | 2010-03-03 | 2013-09-16 |
| STURGE, Simon | Director | 2019-05-01 | 2021-04-08 |
| WALKER-ARNOTT, Edward Ian | Director | 2010-06-01 | 2016-11-23 |
| WELLS, Timothy Nigel Carl, Dr | Director | 2014-07-01 | 2016-11-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Kymab Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-11-23 | Active |
Filing timeline
Last 20 of 174 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-26 | AP01 | officers | Appoint person director company with name date | |
| 2026-03-25 | TM01 | officers | Termination director company with name termination date | |
| 2025-12-12 | AA | accounts | Accounts with accounts type full | |
| 2025-10-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-20 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-10-13 | AA | accounts | Accounts with accounts type full | |
| 2024-09-13 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-01-06 | DISS40 | gazette | Gazette filings brought up to date | |
| 2024-01-04 | AA | accounts | Accounts with accounts type full | |
| 2023-12-12 | GAZ1 | gazette | Gazette notice compulsory | |
| 2023-03-23 | AA | accounts | Accounts with accounts type full | |
| 2022-09-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-02-03 | AA01 | accounts | Change account reference date company previous shortened | |
| 2021-12-21 | AA | accounts | Accounts with accounts type full | |
| 2021-10-28 | AA01 | accounts | Change account reference date company previous shortened | |
| 2021-10-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-01 | TM01 | officers | Termination director company with name termination date | |
| 2021-10-01 | TM01 | officers | Termination director company with name termination date | |
| 2021-09-08 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
+142.9%
£28,000 £68,000
-
Net assets
-77.7%
-£484,372,000 -£860,955,000
-
Employees
-38.6%
145 89
-
Operating profit
-91.7%
-£182,803,000 -£350,414,000
-
Profit before tax
-94.3%
-£196,948,000 -£382,598,000
-
Wages
-13.5%
£10,117,000 £8,755,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers